Gradient Investments’s Genmab GMAB Stock Holding History

Gradient Investments’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10	Closed	-$378	–	1817
2023 Q1	$378	Hold	10	–	–	﹤0.01%	1314
2022 Q4	$424	Buy	+10	New	+$412	﹤0.01%	1317

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Gradient Investments's GMAB Position: Q2 2023 in Review

Gradient Investments sold out of Genmab (GMAB) in Q2 2023, closing a stake of 10 shares — an estimated $378 sold.

Gradient Investments first reported a position in GMAB in Q4 2022 and held it in 2 quarters. The position peaked at $424 in Q4 2022. 213 funds tracked by Wall St. Rank hold GMAB as of Q2 2023.

Gradient Investments reported no remaining Genmab position as of Q2 2023 after selling out during the quarter.
Gradient Investments sold 10 Genmab shares in Q2 2023, an estimated $378.
Gradient Investments first reported a position in Genmab in Q4 2022 and held it in 2 quarters.
Gradient Investments's Genmab position peaked at $424 in Q4 2022.
213 funds tracked by Wall St. Rank held Genmab as of Q2 2023.

Based on Gradient Investments's 13F filing for Q2 2023, filed 11 Jul 2023.